Background
==========

Breast cancer is the most common cancer in women, affecting at least 1 in 10 women in the western world. The potential to predict breast cancer and offer preventive measures is an effective intervention in women with an inherited predisposition to breast cancer due to mutations in *BRCA1/2* genes \[[@B1]\]. However, these account for less than 10% of breast cancers \[[@B2]\]. While extensive genome-wide association studies have identified a number of single nucleotide polymorphisms (SNPs) associated with breast cancer risk \[[@B3]\], epidemiological models that include risk associated SNPs yield a receiver-operating-characteristic (ROC) area under the curve (AUC) of only 62%, a modest 4% improvement over the AUC of epidemiological models \[[@B4]\].

Predicting the likelihood of breast cancer development is therefore still challenging not only because the sensitivity of current strategies is low \[[@B4]\] but also because 11% to 52% of screen-detected breast cancers may be an over diagnosis of cancers which would have never become clinically evident \[[@B5]-[@B7]\]. Hence a biomarker that could predict the risk of developing breast cancer particularly in those with a poor prognosis and which is also independent of familial predisposition is urgently needed.

It is known that epigenetic variation contributes to inter-individual variation in gene expression and thus may contribute to variation in cancer susceptibility \[[@B8]-[@B10]\]. DNAme is the most studied mechanism of epigenetic gene regulation and represents a biologically and chemically stable signal. Aberrant DNA methylation is also a hallmark of cancer \[[@B9],[@B11]\], in particular increased promoter DNAme at stem cell differentiation genes (Polycomb-Repressive Complex 2 (PRC2) Group Target genes (PCGTs)) \[[@B12]-[@B19]\]. Initial evidence suggests that *BRCA1* is a key negative modulator of PRC2 and that loss of *BRCA1* inhibits stem cell differentiation and enhances an aggressive breast cancer phenotype by affecting PRC2 function \[[@B20]\]. Several proof of principle studies using a target gene approach or assessment of global DNA methylation analysing samples collected at the time of diagnosis provided the first evidence for the feasibility of breast cancer risk prediction using DNA methylation based markers \[[@B21]-[@B32]\]. It was also recently demonstrated that DNAme profiles in blood are able to predict cancer risk (on average 1.3 years in advance) within a group of women whose sisters had developed breast cancer \[[@B33]\].

Here we tested the hypothesis that women with an extremely high breast cancer risk (due to a *BRCA1* mutation) carry a specific methylation signature in peripheral blood cells, which is also able to predict sporadic breast cancer incidence and death. We also tested whether this signature is tissue-specific.

Methods
=======

Data from three different studies were used.

BRCA1 study
-----------

We analysed whole blood samples from two cohorts of *BRCA1* mutation carriers and controls without a *BRCA1* mutation (see Figure [1](#F1){ref-type="fig"} and Additional file [1](#S1){ref-type="supplementary-material"}).

![**Study design and identification/validation of the*BRCA1*-mutation DNAme risk signature.** AUC, receiver operating characteristics area under the curve; BC, breast cancer; FDR, false discovery rate; inv., invasive; WBC, white blood cells.](gm567-1){#F1}

MRC National Survey of Health and Development (NSHD)
----------------------------------------------------

We analysed both blood cells and buccal cells from a sample of women from the NSHD, a birth cohort study of men and women born in Britain in March 1946 \[[@B34]-[@B36]\]. A total of 152 (75 cancer cases and 77 controls) women were selected from those who provided both a peripheral blood and a buccal cell sample at the age of 53 years in 1999, who had not previously developed any cancer and who had complete information on epidemiological variables of interest and follow-up. We analysed \>480,000 CpGs (using the Illumina 450 k array) in the 46 women who developed an invasive non-skin cancer (19 breast cancer, 5 reproductive tract and 22 other cancers; diagnosed 1 to 7 years after 53 years and an average of 4.75 years) and in the women (n = 77) who did not develop any cancer during the 12-year follow-up (for descriptive analysis see Additional file [2](#S2){ref-type="supplementary-material"}).

United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)
------------------------------------------------------------------------

We analysed serum DNA samples (which largely represent white blood cell DNA in this cohort - see Additional files [3](#S3){ref-type="supplementary-material"} and [4](#S4){ref-type="supplementary-material"}) from postmenopausal women who developed breast cancer (n = 119) or remained cancer-free during the follow-up period (n = 122, maximum of 12 year follow-up (2001 to 2013)).

Ethics
------

All studies were approved by the relevant research ethics committee or institutional review board. Informed consent was obtained by all volunteers and conforms with the Declaration of Helsinki. The *BRCA1* study was approved by the ethics committee of the General University Hospital, Prague (No. 1199/07 S-IV). The NSHD epigenetics study was approved by the Central Manchester Research Ethics Committee (REC reference: 07/H1008/168). UKCTOCS was approved by the UK North West Multicentre Research Ethics Committees (North West MREC 00/8/34). Ethical approval for this nested case control study was obtained from the Joint UCL/UCLH Committees on the Ethics of Human Research (REC reference: 06/Q0505/102).

DNA methylation analysis
------------------------

The DNA from whole blood and tissues was extracted at UCL \[[@B36]\] and at Gen-Probe \[[@B37]\]. Methylation analysis was performed using the validated Illumina Infinium Human Methylation27 BeadChip \[[@B16]\] or the Illumina Infinium Human Methylation450 BeadChip for NSHD samples. The methylation status of a specific CpG site was calculated from the intensity of the methylated (M) and unmethylated (U) alleles, as the ratio of fluorescent signals β = Max(M,0)/(Max(M,0) + Max(U,0) + 100). On this scale, 0 \< β \< 1, with β values close to 1 (0) indicating 100% methylation (no methylation) (see Additional file [4](#S4){ref-type="supplementary-material"}).

Data availability
-----------------

Data from two of the studies in this manuscript have been deposited in the Gene Expression Omnibus repository under the accession numbers (GSE58119), (GSE57285), (GSE32396). The NSHD data are made available to researchers who submit data requests to mrclha.swiftinfo\@ucl.ac.uk; see full policy documents at \[[@B38]\]. Managed access is in place for this 68-year-old study to ensure that use of the data is within the bounds of consent given previously by participants, and to safeguard any potential threat to anonymity since the participants are all born in the same week.

Statistical analyses
====================

Differential methylation analysis
---------------------------------

From the *BRCA1* study, differentially methylated CpGs, with false discovery rate (FDR) corrected *P* values, between *BRCA1* mutant carriers and *BRCA1* wild type samples were identified via a multivariate logistic regression that was adjusted for age, batch and the presence of cancer.

Ensemble signature identification
---------------------------------

The elastic net classification method was chosen for our study as it has been shown to be particularly effective when the number of predictors is far greater than the number of training points \[[@B39]\]. The elastic net method, as implemented in the glmnet R-package \[[@B40]\], identified a classifier comprising 1,829 CpGs with non-zero regression coefficients (see Additional file [4](#S4){ref-type="supplementary-material"}).

Validation
----------

To evaluate its predictive accuracy, the identified classifier was tested on two independent datasets: (1) NSHD, and (2) UKCTOCS. For each individual, risk scores, based on their methylation profiles, were estimated and correlated to their disease status. An AUC value was then obtained via Somers' Dxy rank correlation \[[@B41]\] (see Additional file [4](#S4){ref-type="supplementary-material"}).

Results
=======

DNA methylation signature in white blood cells (WBC) associated with *BRCA1* mutation status
--------------------------------------------------------------------------------------------

We analysed DNAme of 27,578 CpGs in WBC samples from a total of 72 women with a known *BRCA1* mutation and 72 women with no mutation in the *BRCA1* or *BRCA2* gene (Figure [1](#F1){ref-type="fig"} and Additional file [1](#S1){ref-type="supplementary-material"}). The presence of a cancer has been shown to modulate the composition of WBCs and DNAme profiles in peripheral blood \[[@B42]\] and hence we used a mixture of women who did and who did not develop breast cancer in order to be able to adjust for this. Using a multivariate regression model that included age, cohort and cancer status as covariates we were able to rank CpGs according to the significance of the association between their DNAme profile and mutation status. On applying a relaxed threshold of FDR \<0.3 we observed a total of 2,514 *BRCA1*-mutation associated CpGs, of which 1,422 (57%) were hypermethylated (hyperM) and 1,092 (43%) were hypomethylated (hypoM) in women who had a *BRCA1* mutation (Figure [1](#F1){ref-type="fig"}, Additional file [5](#S5){ref-type="supplementary-material"}), representing a highly significant skew towards hypermethylated CpGs (Binomial test *P* \< 1e-10). To arrive at a specific DNAme signature, which would allow classification of independent samples, we used the elastic net (ELNET) framework (see Additional file [4](#S4){ref-type="supplementary-material"}), which resulted in a signature consisting of 1,829 CpGs (Figure [2](#F2){ref-type="fig"}, Additional file [6](#S6){ref-type="supplementary-material"}).

![**CpGs (n = 1829), which are differentially methylated in WBCs between*BRCA1*mutation carriers and wild type controls and which comprise the '*BRCA1*-mutation DNA methylation signature'.** Heatmap of normalised methylation values (blue = relative high methylation, yellow = relative low methylation) of CpGs comprising the *BRCA1*-mutation DNAme signature. The first colour bar at the top denotes the two main clusters where 'red' reflects the samples with a *BRCA1* mutation whereas 'green' reflects samples without a mutation in *BRCA1* or *BRCA2* gene. The distribution of cancer cases is given in the second colour bar indicating women who had developed a breast cancer in purple. Right panel shows the enrichment of the top components of the gene set enrichment analysis in the hyper- and hypomethylated subset of CpGs; PCGT; Polycomb repressor complex 2 Group Target. Dashed line separates hypermethylated from hypomethylated CpGs.](gm567-2){#F2}

Given that PCGT methylation is a hallmark of almost all cancers and that a *BRCA1* defect in normal non-neoplastic cells is likely to silence PCGTs and compromise cell differentiation \[[@B20]\], we posited that our *BRCA1* DNAme signature may be able to predict sporadic breast cancer. Interestingly, Gene Set Enrichment Analysis (GSEA) \[[@B43],[@B44]\] on the 1,074 hypermethylated (Additional file [7](#S7){ref-type="supplementary-material"}) and 755 hypomethylated (Additional file [8](#S8){ref-type="supplementary-material"}) CpGs of the *BRCA1-*mutation signature demonstrated the association of *BRCA1* mutation with promoter hypermethylation of PCGTs. Indeed, the top categories of genes, associated with the hypermethylated CpGs in *BRCA1* mutation carriers, were significantly (*P* \<10^-10^) enriched for stem cell PCGTs irrespective of the definition used (Figure [2](#F2){ref-type="fig"}, Additional file [7](#S7){ref-type="supplementary-material"}). In contrast, none of the gene categories associated with those CpGs which are hypomethylated in *BRCA1* mutation carriers reached significance based on adjusted *P* values (Additional file [8](#S8){ref-type="supplementary-material"}). Even the GSEA on the 105 CpGs with a more stringent FDR (\<=0.05) associated with *BRCA1* mutation in white blood cells demonstrated the enrichment of PCGTs (*P* \< =0.02) (Additional file [9](#S9){ref-type="supplementary-material"}).

*BRCA1*-mutation DNAme signature and breast cancer risk in peripheral blood cells in the NSHD
---------------------------------------------------------------------------------------------

In order to test whether the *BRCA1*-mutation DNAme signature is able to identify women who will develop breast cancer we analysed one of the best available characterised longitudinal cohorts (Additional file [2](#S2){ref-type="supplementary-material"}). Applying the *BRCA1*-mutation DNAme signature (out of the 1,829 *BRCA1* CpGs, 1,722 were present on the 450 k Illumina methylation array), yielded a breast cancer risk AUC = 0.65 (0.51 to 0.78, *P* = 0.02) (Figure [3](#F3){ref-type="fig"}A). Interestingly, the *BRCA1* signature also significantly predicted the future development of invasive non-breast cancers (AUC = 0.62; 0.50 to 0.74; *P* = 0.04) (Additional file [10](#S10){ref-type="supplementary-material"}A).

![**Validation of the*BRCA1*-mutation DNAme signature in two independent prospective cohorts.** ROC curves and AUC statistics to predict future breast cancer (BC) incidence applying the *BRCA1*-mutation DNAme signature in white blood cells (WBCs) **(A)** and in buccal (BUCC) cells **(B)** of the NSHD cohort and in serum DNA of the UKCTOCS cohort **(C)**. Overlap of the top CpGs differently methylated in WBC between *BRCA1* mutant and wild type (*BRCA1* study) and the top CpGs differently methylated in serum DNA between women who have developed oestrogen receptor positive BCs and women who remained cancer-free **(D)**. ROC curve and AUC statistics to predict deadly BCs applying the *BRCA1*-mutation DNAme signature in serum DNA in the UKCTOCS cohort **(E)** and Kaplan Meier curve (and hazard ratio (HR)) of future breast cancer patients with a high and low *BRCA1*-mutation DNAme score in serum DNA **(F)**.](gm567-3){#F3}

Consistent with the view that DNAme is tissue-specific, our DNAme signature - derived from peripheral blood cells from women with known *BRCA1* status - was not able to predict invasive breast cancer (Figure [3](#F3){ref-type="fig"}B) or invasive non-breast cancer (Additional file [10](#S10){ref-type="supplementary-material"}B) in the buccal cell DNAme profiles obtained at the same time from the same women who provided blood DNA.

*BRCA1-*mutation DNA methylation signature and breast cancer risk in serum DNA in the UKCTOCS cohort
----------------------------------------------------------------------------------------------------

Less than 10% of invasive breast cancers are due to a *BRCA1* mutation \[[@B45]\] and therefore it is unlikely that the predictive capacity of the *BRCA1*-mutation DNAme signature in the NSHD cohort was due to the correct identification of *BRCA1* mutation carriers. Nevertheless in order to further substantiate that the *BRCA1*-mutation DNAme signature identifies sporadic cancers, we performed a nested case--control study within the UKCTOCS cohort (a 202,638 postmenopausal women cohort, who based on their family history were not at an increased risk of ovarian or breast cancer - see Additional files [3](#S3){ref-type="supplementary-material"} and [4](#S4){ref-type="supplementary-material"}). As *BRCA1*-associated cancers are far more likely (75%) to be oestrogen receptor (ER) negative \[[@B46]\], we solely focused our analysis on women who provided a blood sample between 0.42 and 4.18 years (average 2 years) before they developed an ER positive invasive breast cancer (n = 119) and matched (on age at blood donation and recruitment centre) them to 122 women who did not develop a breast cancer during the follow-up period (5.61 to 12 years, average follow-up 11.92 years). As there was no whole blood DNA samples available from the women in UKCTOCS, we used serum-free DNA as a source of material for this analysis. Since \>95% of blood samples were only spun down 24 to 48 h after the blood draw, it was important for us to identify the likely source of DNA in the serum samples. Although we were not able to definitely identify the source, the evidence clearly pointed towards an enriched for WBC DNA (see Additional file [11](#S11){ref-type="supplementary-material"}). The *BRCA1*-mutation DNAme signature predicted the development of an ER positive breast cancer with an AUC = 0.57 (0.50 to 0.64; *P* = 0.03) (Figure [3](#F3){ref-type="fig"}C) independent of whether the sample was taken less or more than 2 years prior to diagnosis (see Additional file [12](#S12){ref-type="supplementary-material"}). Importantly, the *BRCA1-*mutation DNAme signature also substantially overlapped with an ER + breast cancer specific risk signature (Additional file [13](#S13){ref-type="supplementary-material"}), which we derived *de novo* in the UKCTOCS cohort (*P* \<2 x 10^-33^, Figure [3](#F3){ref-type="fig"}D). Of note, in the breast cancer specific risk signature, we also observed enrichment of biological terms, all crucially involved in stem cell differentiation and biology (Additional file [14](#S14){ref-type="supplementary-material"}). Again, these stem cell gene categories were only enriched among CpGs hypermethylated in cases, but not among CpGs hypomethylated in cases (Additional file [15](#S15){ref-type="supplementary-material"}). This observation is particularly pertinent given that NIPP1, PRC2, MSX1 and NANOG all suppress differentiation through occupation and suppression of specific gene sets.

*BRCA1*-mutation DNAme signature identifies women years in advance of fatal breast cancer diagnosis
---------------------------------------------------------------------------------------------------

In order to test whether the *BRCA1*-mutation DNAme signature is able to predict not only incidence but also breast cancer mortality we performed ROC statistics in the UKCTOCS set comparing women who died from breast cancer (n = 10) during the follow-up period with women who did not develop breast cancer (Figure [3](#F3){ref-type="fig"}E) and found an AUC = 0.67 (0.51 to 0.83; *P* = 0.02). In line with these findings women with a higher than average *BRCA1*-mutation DNAme signature score were 8.46 (95% CI 1.06 to 67.69) -fold more likely to die from breast cancer (*P* = 0.04) than those with lower than average scores (Figure [3](#F3){ref-type="fig"}F). Interestingly, apart from the number of nodes, none of the other clinico-pathological features or treatment modalities was associated with the *BRCA1*-mutation DNAme signature in these ER positive breast cancers (Additional file [16](#S16){ref-type="supplementary-material"}).

*BRCA1*-mutation DNAme signature and association with epidemiological and hormonal risk markers
-----------------------------------------------------------------------------------------------

Next, we were interested whether our DNAme signature could be explained by any of the breast cancer risk factors we had available for the UKCTOCS cohort. Interestingly, neither any of the epidemiological breast cancer risk factors nor any of the hormones (Tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}) we have analysed in the same serum samples was associated with our *BRCA1*-mutation DNAme signature. Interestingly, when we analysed women with and without a family history \[[@B47]\] separately, both BC incidence and death was predicted by our *BRCA1*-DNAme signature only in the group without family history (Additional file [17](#S17){ref-type="supplementary-material"}), but not in the (obviously very small) group of women with any family history (Additional file [18](#S18){ref-type="supplementary-material"}).

###### 

Characteristics of the samples used from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)

  **Factors**                             **Methylation signature**   ***P*value**   
  --------------------------------- ----- --------------------------- -------------- --------
  OCP use in the past               Yes   72                          60             0.604
                                    No    55                          54              
  Pregnancies \<6 months            Yes   32                          35             0.387
                                    No    95                          78              
  Pregnancies \>6 months            Yes   109                         102            0.439
                                    No    18                          12              
  Mother breast cancer              Yes   14                          11             0.833
                                    No    113                         103             
  Grandmother(s) breast cancer      Yes   2                           7              0.0887
                                    No    125                         107             
  Sister(s) breast cancer           Yes   5                           11             0.118
                                    No    122                         103             
  Aunt(s) breast cancer             Yes   12                          6              0.233
                                    No    115                         108             
  Any family member breast cancer   Yes   29                          32             0.376
                                    No    98                          82              
  Alcohol units per week            Yes   78                          68             1
                                    No    26                          23              
  Smoker                            Yes   41                          37             0.89
                                    No    84                          72              

The samples were categorised according to their individual risk scores. These risk scores are the product of the methylation profile with the regression coefficients of the signature. The statistical significance was assessed by a two-sided, Fisher's exact test. The missing values were excluded from the analysis.

###### 

Additional characteristics of the samples used from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)

                                  **Breast cancer (\#Samples)**   **Methylation signature**   ***P*value**   
  ------------------------------- ------------------------------- --------------------------- -------------- ------
  Mean BMI (kg/m^2^)              Yes (119)                       27.39 (5.3)                 27.27 (5.0)    0.9
                                  No (121)                        26.63 (5.17)                26.57 (4.64)   0.95
  Mean age at menarche (years)    Yes (117)                       12.89 (1.48)                12.65 (1.61)   0.4
                                  No (122)                        12.97 (1.76)                13.24 (1.77)   0.39
  Mean age at menopause (years)   Yes (119)                       49.58 (5.78)                48.37 (7.65)   0.34
                                  No (122)                        47.57 (7.99)                48.74 (5.79)   0.36

The samples were categorised according to their individual risk scores. These risk scores are the product of the methylation profile with the regression coefficients of the signature. The statistical significance was assessed by a t-test. The missing values were excluded from the analysis.

###### 

Characteristics of the samples used from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)

  **Hormones**                    **Breast cancer (\#Samples)**   **Methylation signature**   ***P*value**    
  ------------------------------- ------------------------------- --------------------------- --------------- ------
  Mean oestradiol, pg/mL          Yes (65)                        20.51 (16.74)               18.67 (10.09)   0.59
                                  No (115)                        17.36 (8.32)                19.24 (8.11)    0.22
  Mean free oestradiol, pmol/L    Yes (65)                        0.98 (0.58)                 0.99 (0.55)     0.95
                                  No (114)                        0.84 (0.43)                 1.02 (0.59)     0.05
  Mean oestrone, pg/mL            Yes (67)                        126.7 (156.59)              97.22 (58.10)   0.31
                                  No (117)                        112.7 (91.86)               97.55 (92.41)   0.38
  Mean androstendione, nmol/L     Yes (64)                        3.35 (1.66)                 3.96 (2.00)     0.19
                                  No (118)                        3.4 (2.10)                  3.13 (1.41)     0.41
  Mean testosterone, nmol/L       Yes (65)                        0.30 (0.17)                 0.35 (0.20)     0.3
                                  No (115)                        0.28 (0.17)                 0.31 (0.19)     0.42
  Mean free testosterone, ng/dl   Yes (65)                        0.12 (0.08)                 0.14 (0.10)     0.35
                                  No (115)                        0.11 (0.07)                 0.13 (0.09)     0.17
  Mean SHBG, nmol/L               Yes (66)                        57.54 (37.71)               49.79 (19.86)   0.24
                                  No (116)                        61.26 (26.46)               54.49 (24.36)   0.16
  Mean progesterone, ng/mL        Yes (66)                        0.63 (2.13)                 0.28 (0.21)     0.34
                                  No (114)                        0.27 (0.17)                 0.28 (0.16)     0.84
  Mean DHEAS, ug/dl               Yes (66)                        109.6 (57.54)               92.52 (56.75)   0.23
                                  No (116)                        115.8 (65.49)               107.1 (57.92)   0.45
  Mean ER alpha, pg/mL            Yes (67)                        89.67 (87.33)               81.23 (56.48)   0.64
                                  No (120)                        69.54 (62.56)               75.29 (61.84)   0.61
  Mean ER beta, pg/mL             Yes (67)                        87.06 (122.37)              64.01 (75.85)   0.35
                                  No (120)                        56.74 (62.83)               60.95 (72.14)   0.73
  Mean AR, ng/mL                  Yes (67)                        2.5 (0.95)                  2.4 (0.91)      0.78
                                  No (119)                        2.28 (1.11)                 2.45 (0.96)     0.37

The samples were categorised according to their individual risk scores. These risk scores are the product of the methylation profile with the regression coefficients of the signature. The statistical significance was assessed by a t-test. The missing values were excluded from the analysis.

Discussion
==========

Here we have provided several novel lines of evidence indicating that DNAme profiles obtained in cells from women with a *BRCA1* mutation have the potential to indicate future breast cancer development (and death) many years in advance of diagnosis. Our findings also show that genes encoding developmental transcription factors integral for stem cell differentiation and biology are hypermethylated in women predisposed to breast cancer.

Our data suggest that the *BRCA1*-associated DNAme signature is a risk predicting signature rather than an early detection signature, because: (1) the DNAme signature was derived from WBCs in women with a known *BRCA1* status and was adjusted for cancer status (analysis included *BRCA1* carriers without cancer at the time of sample draw); (2) the time from sample draw to diagnosis had no dramatic impact on the strength of association between DNAme and potential for breast cancer development; (3) the signature was validated in two independent cohorts; (4) we observed a very strong overlap of CpGs associated with *BRCA1* mutation (*BRCA1* study) and CpGs indicating future breast cancer risk (UKCTOCS); and finally (5) the signature was also associated with invasive non-breast cancers.

The observation that the top ranked hypermethylated *BRCA1*-mutation associated CpGs are highly enriched for PCGTs which we and others have previously shown to be an epigenetic hallmark of cancer tissue \[[@B12]-[@B18]\] and which are among the earliest, if not the earliest, molecular changes in human carcinogenesis \[[@B18]\] was an exciting finding because it fully supports recent data demonstrating that a *BRCA1* defect leads to retargeting of the PRC2 and reduces cell differentiation.

Two key issues remain unclear. First, which factors lead to a *BRCA1*-mutation DNAme pattern in the absence of a *BRCA1* mutation? It is likely that a combination of risk factors or factors which we have not captured (for example, early life events, transgenerational inheritance, and so on) contribute to epigenetic modifications which are in common to those associated with *BRCA1* mutation. Second, is the *BRCA1*-mutation DNAme signature in WBCs functionally relevant or just simply an indicator of breast cancer risk? The fact that the signature is indicative of breast cancer mortality would support the view that subtle epigenetic mis-programming of immune cells may lead to general immune defects which in turn supports the development and proliferation of cancers. However, all these suggestions are highly speculative and need validation in further independent cohorts using well-defined subsets of blood cells or epithelial cells.

There are limitations to this study. First, we analysed whole blood DNA or serum DNA representing whole blood DNA and not a specific subset of peripheral blood cells. Second, although we found some good preliminary evidence that DNAme profiles in buccal cells are better at predicting future breast cancer risk (data not shown), we did not analyse buccal cells from *BRCA1* mutation carriers, nor did we have access to independent prospective buccal cell data. Third, we used the 27 k array, instead of the 450 k array, to generate the *BRCA1*-mutation DNAme signature.

In summary, our data highlight DNAme analysis as a promising tool to predict future breast cancer development. Future epigenome-wide studies should focus on using epithelial cells like buccal - or epithelial cells from the uterine cervix which are hormone sensitive and more likely to capture an 'epigenetic record' of breast cancer risk factors. Such studies are more likely to provide the level of specificity and sensitivity which is required for a clinically useful risk prediction tool.

Conclusions
===========

In summary, our DNAme signature derived from blood cells from *BRCA1* carriers is able to predict breast cancer risk and death years in advance of diagnosis albeit with a modest AUC. Our data further support the notion that DNAme modification at stem-cell differentiation genes, even in unrelated tissues, is an early event associated with carcinogenesis.
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**Average number of differentially methylated CpGs between tissue types.** UKOPS WB = whole blood from postmenopausal healthy women; T1D WB = whole blood from pre and postmenopausal women with type-1 diabetes.
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###### Additional file 12

ROC curve of the identified signature on the UKCTOCS dataset, separated around the diagnosis time of less than/greater than 2 years.
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###### Additional file 13

Top ranked 5482 CpGs associated with future breast cancer risk from serum DNA in the UKCTOCS set.
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###### Additional file 14

Gene Set Enrichment Analysis on the top 3395 hypermethylated CpGs in the UKCTOCS cohort using a multivariate linear regression framework.
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###### Additional file 15

Gene Set Enrichment Analysis on the top 2087 hypomethylated CpGs in the UKCTOCS cohort using a multivariate linear regression framework.
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###### Additional file 16

**Characteristics of the samples used from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).** The samples were categorised according to their individual risk scores. These risk scores are the product of the methylation profile with the regression coefficients of the signature. The statistical significance was assessed by a two-sided, Fisher's exact test. The missing values were not included in the analysis.
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###### Additional file 17

ROC curve of the identified signature on the UKCTOCS dataset samples, without a family history of breast cancer, separated into breast cancer incidence and breast cancer mortality.
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###### Additional file 18

ROC curve of the identified signature on the UKCTOCS dataset samples, with a family history of breast cancer, separated into breast cancer incidence and breast cancer mortality.
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